Acrivon Therapeutics Inc [ACRV] stock is trading at $6.97, up 17.94%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ACRV shares have gain 25.59% over the last week, with a monthly amount glided 5.29%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Ladenburg Thalmann upgraded its rating to Buy on September 16, 2024, and kept the price target unchanged to $16. On April 29, 2024, downgrade downgraded it’s rating to Neutral. JMP Securities started tracking the stock assigning a Mkt Outperform rating and suggested a price target of $14 on March 01, 2024. In a note dated June 02, 2023, Oppenheimer initiated an Outperform rating and provided a target price of $25 on this stock.
Acrivon Therapeutics Inc [ACRV] stock has fluctuated between $3.19 and $11.90 over the past year. Currently, Wall Street analysts expect the stock to reach $22.5 within the next 12 months. Acrivon Therapeutics Inc [NASDAQ: ACRV] shares were valued at $6.97 at the most recent close of the market. An investor can expect a potential return of 222.81% based on the average ACRV price forecast.
Analyzing the ACRV fundamentals
Gross Profit Margin for this corporation currently stands at 0.7% with Operating Profit Margin at -45.27%, Pretax Profit Margin comes in at -40.86%, and Net Profit Margin reading is -40.86%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.48 and Total Capital is -0.43. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.87 points at the first support level, and at 4.76 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.04, and for the 2nd resistance point, it is at 9.10.
Ratios To Look Out For
For context, Acrivon Therapeutics Inc’s Current Ratio is 12.75. In addition, the Quick Ratio stands at 12.75 and the Cash Ratio stands at 2.93.
Transactions by insiders
Recent insider trading involved PERCEPTIVE ADVISORS LLC, 10% Owner, that happened on Apr 11 ’24 when 2.35 million shares were purchased.
